appliedclinicaltrialsonline1d
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...
rarediseaseadvisor1d
Sotatercept-csrk’s Success in PAH Results in Early Termination of HYPERION Trial
The decision to terminate the HYPERION trial reflects a loss of clinical equipoise, making it unethical to continue the placebo-controlled study.
Managed Healthcare Executive2d
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH
Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...
thecardiologyadvisor.com3d
Sotatercept Trial Ends Due to Positive Clinical Program Efficacy Data
The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.
Healio4d
Winrevair PAH trial stopped due to earlier ‘robust evidence’
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...